Latest News about JNJ
Recent news which mentions JNJ
From InvestorPlace
Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January
January 11, 2024
From Motley Fool
Why Eli Lilly Stock Skyrocketed 59% in 2023
January 11, 2024
From Motley Fool
From Motley Fool
3 Unshakeable Dividend Stocks for Lifelong Wealth
January 10, 2024
From InvestorPlace
7 Stable Stocks to Buy No Matter What Happens to Interest Rates
January 10, 2024
From InvestorPlace
A Closer Look at Johnson & Johnson's Options Market Dynamics
January 10, 2024
Tickers
JNJ
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 09, 2024
From Benzinga
Illumina Shares Trading Higher After Confirming Partnership With Johnson & Johnson Unit
January 09, 2024
From Benzinga
Want to Win in the Stock Market? Be Average.
January 09, 2024
From Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 08, 2024
From Benzinga
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
January 08, 2024
From InvestorPlace
J&J's Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States
January 08, 2024
From Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
From Benzinga
From Benzinga
24 Top Dividend Stocks to Buy and Hold in 2024
January 07, 2024
From Motley Fool
5 Top Investing Resolutions for 2024
January 07, 2024
From Motley Fool
Dow Darlings: Top 3 Stocks That Will Lead the Charge in 2024
January 06, 2024
From InvestorPlace
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
From Benzinga
Illumina's MRD Technology For Cancer Testing Collaborates With Johnson & Johnson Unit
January 05, 2024
From Benzinga
Still Worried About a 2024 Recession? 7 Stocks to Watch.
January 04, 2024
From InvestorPlace
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
From Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
From InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
From Benzinga
From Benzinga
3 No-Brainer Stocks to Buy With $1,000 Right Now for the New Year
January 03, 2024
From Motley Fool
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|